Kuikka J T, Bergström K A, Vanninen E, Laulumaa V, Hartikainen P, Länsimies E
Department of Clinical Physiology, Kuopio University Hospital, Finland.
Eur J Nucl Med. 1993 Sep;20(9):783-6. doi: 10.1007/BF00180909.
The iodinated cocaine analogue 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane ([123I]beta-CIT), a new dopamine transporter, was preliminary tested in human brain. Two normal volunteers and two patients with Parkinson's disease were imaged with a high-resolution single-photon emission tomography scanner. The specific binding of [123I]beta-CIT in the basal ganglia and thalamus was high in normal volunteers. In addition, there was relatively intense uptake in the medial prefrontal area. Patients with Parkinson's disease who were older than controls showed significantly lower specific binding in the basal ganglia and thalamus and no uptake in the medial prefrontal cortex. This decrease in the dopamine transporter may be age related.
碘化可卡因类似物2β-甲氧羰基-3β-（4-碘苯基）托烷（[123I]β-CIT），一种新型多巴胺转运体，已在人脑进行了初步测试。两名正常志愿者和两名帕金森病患者用高分辨率单光子发射断层扫描仪进行了成像。正常志愿者中，[123I]β-CIT在基底神经节和丘脑的特异性结合较高。此外，内侧前额叶区域有相对较强的摄取。年龄大于对照组的帕金森病患者在基底神经节和丘脑的特异性结合显著降低，在内侧前额叶皮质无摄取。多巴胺转运体的这种减少可能与年龄有关。
